Lysergamides

The doses, potencies, durations, and effects of lysergamides have been reviewed by Alexander Shulgin.^{[24][25][26][27][28]} They have also been reviewed by Albert Hofmann,^[29] David E. Nichols,^[30] and other researchers.^{[31][32][33][34][35][36][37][38][39]}

The properties of various additional lysergamides, for instance in terms of serotonin antagonism, have also been described.^[50]

Lysergamides, such as ergine, isoergine, and ergometrine, were discovered by the early 1930s,^[18][19][20] and LSD was discovered by 1938 and its hallucinogenic effects in 1943 by Albert Hofmann.^[53][54] Many synthetic lysergamide analogues of LSD, modified at the amide and/or 1 or 2 positions, were first described by Hofmann and colleagues in the mid-to-late 1950s.^{[29][34][42][55]} N(6)-Substituted lysergamides were first reported in 1970 and thereafter in the 1970s and 1980s by multiple groups, including Hofmann and colleagues, Yuji Nakahara and Tetsukichi Niwaguchi and colleagues, and David E. Nichols and colleagues.^{[56][57][58][6]} The psychedelic effects of N(6)-substituted lysergamides were reported by Alexander Shulgin in 1986 and thereafter.^{[59][37][25][28]} Additional novel lysergamides modified at the amide, like LA-3Cl-SB and LA-Aziridine, were described by Nichols and Robert Oberlender and colleagues in the late 1980s,^[60][37][56] while LSZ (LA-Azetidine) was described by the same group in 2002.^[9] Numerous 1-substituted LSD prodrugs such as 1P-LSD and 1V-LSD and other psychedelic lysergamides were developed by Lizard Labs in the 2010s and 2020s.^[61][62][63]

• Substituted ergoline
• Partial lysergamide
• Substituted tryptamine
• Substituted phenethylamine
• Lizard Labs